Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AST-006
- Development stage
- Unknown
- Lead developer
- Ascentawits Pharmaceuticals
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
AST-006 is a small molecule-drug conjugate (SMDC) developed by Ascentawits Pharmaceuticals for the treatment of BRCA-mutated malignant neoplasms, specifically targeting breast and ovarian cancers. The drug is built upon a proprietary platform that conjugates a small-molecule targeting fragment to a cytotoxic chemotherapy payload. This design is intended to leverage the tumor microenvironment to selectively deliver the payload to tumor cells, thereby increasing local efficacy while reducing systemic toxicity. AST-006 has received Investigational New Drug (IND) approval and is currently in Phase I clinical development.
Beyond the preview
Go deeper on AST-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AST-006.